YH32364
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR Overexpression
Conditions
EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial Timeline
Jun 12, 2025 → Dec 1, 2029
NCT ID
NCT06975410About YH32364
YH32364 is a phase 1/2 stage product being developed by Yuhan for EGFR Overexpression. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06975410. Target conditions include EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06975410 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in EGFR Overexpression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH25448 | Yuhan | Phase 1/2 | 41 |
| Datopotamab deruxtecan | Daiichi Sankyo | Pre-clinical | 23 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8273 | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| ASP8273 Capsules + ASP8273 Capsules A | Astellas Pharma | Phase 2 | 52 |
| famitinib po + HS-10296 po | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| AZD9291 40 mg + AZD9291 80 mg | AstraZeneca | Phase 1 | 33 |
| Osimertinib-based adaptive treatment + Osimertinib 80 MG | AstraZeneca | Phase 2 | 52 |
| AZD9291 + MEDI4736 | AstraZeneca | Phase 3 | 77 |
| EGFR TKIs (gefitinib, erlotinib, afatinib, et al) | AstraZeneca | Pre-clinical | 23 |
| AZD9291 | AstraZeneca | Pre-clinical | 23 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| Dasatinib + Osimertinib | AstraZeneca | Phase 1/2 | 41 |
| AZD9291 80mg oral each day | AstraZeneca | Phase 3 | 77 |
| Tremelimumab + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| AZD3759 + AZD9291 | AstraZeneca | Phase 1 | 33 |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85